Ondansetron

Generic Name: Ondansetron

Brand Names: Zofran, Zuplenz

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₃O

CAS Number: 99614-02-5

Unique Ingredient Identifier: 4AF302ESOS

Background: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...

Indication: In the adult patient population:

i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...

Associated Conditions: Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum

Associated Therapies: -

Clinical Trials

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

Phase 1

Completed

Conditions: Postoperative Nausea and Vomiting

Interventions: Drug: Aprepitant
Drug: Ondansetron

First Posted Date: 2009-01-08

Last Posted Date: 2021-01-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 98

Registration Number: NCT00819039

Locations: 🇲🇽
MSD, Mexico City, Mexico
🇹🇷
Merck Sharp & Dohme Ilaclari Ltd. Sti, Istanbul, Turkey
🇪🇸
Merck Sharp and Dohme de Espana S.A., Madrid, Spain

and more 2 locations

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Phase 1

Terminated

Conditions: Chemotherapy-Induced Nausea and Vomiting

Interventions: Drug: Ondansetron
Drug: Dexamethasone

First Posted Date: 2009-01-07

Last Posted Date: 2018-09-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 92

Registration Number: NCT00818259

Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)

Phase 4

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Drug: ondansetron

First Posted Date: 2008-11-24

Last Posted Date: 2011-02-24

Lead Sponsor: Institute of Neuroscience, Florence, Italy

Target Recruit Count: 14

Registration Number: NCT00796497

Locations: 🇮🇹
Institute of Neuroscience, Florence, Italy

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Atypical Chronic Myeloid Leukemia, BCR-ABL Negative
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: ondansetron
Other: survey administration
Procedure: management of therapy complications

First Posted Date: 2008-11-21

Last Posted Date: 2017-05-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00795769

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia

Phase 4

Completed

Conditions: Anaesthetics Gases, Xenon
Anaesthetics Volatile, Sevoflurane
Depth of Anaesthesia
Postoperative Nausea
Postoperative Vomiting

Interventions: Drug: Xenon
Drug: Dexamethasone
Drug: NaCl
Drug: Ondansetron
Drug: Sevoflurane

First Posted Date: 2008-11-19

Last Posted Date: 2011-05-17

Lead Sponsor: RWTH Aachen University

Target Recruit Count: 220

Registration Number: NCT00793663

Locations: 🇩🇪
RWTH Aachen University; Department of Anesthesiology, Aachen, Germany

Uncomplicated Nausea and Vomiting in the Emergency Department

Phase 4

Completed

Conditions: Vomiting
Nausea

Interventions: Drug: Ondansetron
Drug: Metoclopramide

First Posted Date: 2008-10-23

Last Posted Date: 2012-06-28

Lead Sponsor: WellSpan Health

Target Recruit Count: 137

Registration Number: NCT00778011

Locations: 🇺🇸
York Hospital, York, Pennsylvania, United States

Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients

Not Applicable

Completed

Conditions: Postoperative Nausea and Vomiting

Interventions: Drug: Ondansetron
Drug: Dronabinol

First Posted Date: 2008-09-23

Last Posted Date: 2016-05-13

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 216

Registration Number: NCT00757822

Locations: 🇺🇸
Central Arkansas Veterans Healthcare System-John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States

Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)

Phase 4

Completed

Conditions: Irritable Bowel Syndrome With Diarrhoea

Interventions: Drug: Placebo
Drug: Ondansetron

First Posted Date: 2008-09-01

Last Posted Date: 2012-01-24

Lead Sponsor: University of Nottingham

Target Recruit Count: 150

Registration Number: NCT00745004

Locations: 🇬🇧
University Hospital of South Manchester NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
🇬🇧
University of Nottingham, Nottingham, Nottinghamshire, United Kingdom